Home > Publications Database > Health-Related Quality of Life in Patients with Friedreich Ataxia Using Mobility Assistive Technologies: Limited Fit of the EQ-5D-3L Mobility Dimension. > print

001     279169
005     20250709100935.0
024 7 _ |a 10.1007/s40120-024-00694-7
|2 doi
024 7 _ |a pmid:39738982
|2 pmid
024 7 _ |a pmc:PMC11762039
|2 pmc
024 7 _ |a 2193-6536
|2 ISSN
024 7 _ |a 2193-8253
|2 ISSN
037 _ _ |a DZNE-2025-00697
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Buchholz, Maresa
|0 P:(DE-2719)9002138
|b 0
|e First author
245 _ _ |a Health-Related Quality of Life in Patients with Friedreich Ataxia Using Mobility Assistive Technologies: Limited Fit of the EQ-5D-3L Mobility Dimension.
260 _ _ |a Heidelberg [u.a.]
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751966055_3174
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Friedreich Ataxia (FA) is a multisystem neurodegenerative disease. Affected individuals rely on mobility assistive technologies (MAT) (e.g. wheelchairs) and require long-term treatments and care. To analyse the patients' health-related quality of life (HRQoL), the EuroQol 5 Dimension 3 Level survey (EQ-5D-3L)-a widely used and recommended generic measure-is used in clinical and in health economic studies. Concerns about using the instrument in mobility-impaired individuals who might have difficulties finding appropriate response options for mobility-related items led us to investigate how the 3L dimensions perform in patients with FA using or not using MAT.Using longitudinal data from 607 patients with FA of the EFACTS study (from baseline to the 3-year follow-up), we analysed the acceptability, distribution properties, validity, and responsiveness of the EQ-5D-3L, focusing on the mobility item. Analyses were stratified for patients without and with different MAT-usage.We identified that n = 177 patients used no MAT, n = 299 a wheelchair and n = 131 walking aids. The mobility item non-response was highest in wheelchair users (6.8%) and lowest in patients without MAT. Walking aid users showed the least variability, all selecting the mid-response option 'some problems' for mobility. The mobility item correlated moderately with disease severity (rsp = 0.35) and the activities of daily living scale (rsp = 0.36) in wheelchair users. No correlation exists for walking aid users. The strongest health changes occurred for wheelchair users, the weakest for walking aid users. The mobility dimensions showed the highest amount of no changes.The EQ-5D-3L's mobility item has limitations in MAT users, particularly in walking aid users, due to a tendency towards mid-responses. These limitations may affect the efficacy and (cost)effectiveness conclusions drawn from interventions and clinical trials with mobility-impaired individuals. Further research is needed to explore the understanding and interpretation of responses of the EQ-5D in patients with FA with mobility support.ClinicalTrials.gov identifier NCT02069509.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a EQ-5D-3L
|2 Other
650 _ 7 |a Friedreich Ataxia
|2 Other
650 _ 7 |a Health-related quality of life
|2 Other
650 _ 7 |a Mobility assistive technology
|2 Other
700 1 _ |a Pfaff, Michelle
|0 P:(DE-2719)9002113
|b 1
|u dzne
700 1 _ |a Iskandar, Audrey
|0 P:(DE-2719)9003158
|b 2
|u dzne
700 1 _ |a Reetz, Kathrin
|b 3
700 1 _ |a Schulz, Jörg B
|b 4
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 5
|u dzne
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 6
|u dzne
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 7
|e Last author
|u dzne
700 1 _ |a Group, EFACTS Study
|b 8
|e Collaboration Author
700 1 _ |a Boesch, Sylvia
|b 9
|e Contributor
700 1 _ |a Nachbauer, Wolfgang
|b 10
|e Contributor
700 1 _ |a Eigentler, Andreas
|b 11
|e Contributor
700 1 _ |a Indelicato, Elisabetta
|b 12
|e Contributor
700 1 _ |a Amprosi, Matthias
|b 13
|e Contributor
700 1 _ |a Rai, Myriam
|b 14
|e Contributor
700 1 _ |a Pandolfo, Massimo
|b 15
|e Contributor
700 1 _ |a Mariotti, Caterina
|b 16
|e Contributor
700 1 _ |a Nanetti, Lorenzo
|b 17
|e Contributor
700 1 _ |a Gellera, Cinzia
|b 18
|e Contributor
700 1 _ |a Mongelli, Alessia
|b 19
|e Contributor
700 1 _ |a Castaldo, Anna
|b 20
|e Contributor
700 1 _ |a Fichera, Mario
|b 21
|e Contributor
700 1 _ |a Bertini, Enrico
|b 22
|e Contributor
700 1 _ |a Vasco, Gessica
|b 23
|e Contributor
700 1 _ |a Durr, Alexandra
|b 24
|e Contributor
700 1 _ |a Ewenczyk, Claire
|b 25
|e Contributor
700 1 _ |a Biet, Marie
|b 26
|e Contributor
700 1 _ |a Monin, Marie Lorraine
|b 27
|e Contributor
700 1 _ |a Holtbernd, Florian
|b 28
|e Contributor
700 1 _ |a Brcina, Nikolina
|b 29
|e Contributor
700 1 _ |a Hohenfeld, Christian
|b 30
|e Contributor
700 1 _ |a Didszun, Claire
|b 31
|e Contributor
700 1 _ |a Dogan, Imis
|b 32
|e Contributor
700 1 _ |a Giordano, Ilaria
|0 P:(DE-2719)2811662
|b 33
|e Contributor
|u dzne
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 34
|e Contributor
|u dzne
700 1 _ |a Stendel, Claudia
|b 35
|e Contributor
700 1 _ |a Radelfahr, Florentine
|b 36
|e Contributor
700 1 _ |a Bischoff, Almut
|0 P:(DE-2719)9003293
|b 37
|e Contributor
|u dzne
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 38
|e Contributor
|u dzne
700 1 _ |a Hayer, Stefanie
|0 P:(DE-2719)2813263
|b 39
|e Contributor
|u dzne
700 1 _ |a Koutsis, Georgios
|b 40
|e Contributor
700 1 _ |a Breza, Marianthi
|b 41
|e Contributor
700 1 _ |a Palau, Francesc
|b 42
|e Contributor
700 1 _ |a O'Callaghan, Mar
|b 43
|e Contributor
700 1 _ |a de Rivera Garrido, Francisco Javier Rodríguez
|b 44
|e Contributor
700 1 _ |a Rummey, Christian
|b 45
|e Contributor
700 1 _ |a Giunti, Paola
|b 46
|e Contributor
700 1 _ |a Parkinson, Michael H
|b 47
|e Contributor
700 1 _ |a Thomas-Black, Gilbert
|b 48
|e Contributor
700 1 _ |a Manso, Katarina
|b 49
|e Contributor
700 1 _ |a Solanky, Nita
|b 50
|e Contributor
700 1 _ |a Labrum, Robyn
|b 51
|e Contributor
773 _ _ |a 10.1007/s40120-024-00694-7
|g Vol. 14, no. 1, p. 379 - 398
|0 PERI:(DE-600)2682228-3
|n 1
|p 379 - 398
|t Neurology and Therapy
|v 14
|y 2025
|x 2193-6536
856 4 _ |u https://pub.dzne.de/record/279169/files/DZNE-2025-00697%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/279169/files/DZNE-2025-00697.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/279169/files/DZNE-2025-00697%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/279169/files/DZNE-2025-00697.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:279169
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002138
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002113
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9003158
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001510
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2810763
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 33
|6 P:(DE-2719)2811662
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 34
|6 P:(DE-2719)2810704
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 37
|6 P:(DE-2719)9003293
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)2810795
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 39
|6 P:(DE-2719)2813263
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL THER : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:42:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:42:53Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 1
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 2
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 3
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21